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Abstract

THE EFFECTS OF TARSH OVEREXPESSION ON LUNG CELL CARCINOMAS
By Young Min Kim, M.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Major Director: Dr. Hiroshi Miyazaki, M.D., Ph.D.
Philips Institute, VCU School of Dentistry

Lung cancer arises from epithelial cells that line the air passages of the lungs. It is
the second most common malignancy in the United States; trends suggest that over
228,000 new patients will be diagnosed with lung cancer in 2013. Due to the fact that lung
cancer is highly aggressive, it has proven difficult to control. The 5-year survival rate has
been shown to be only 15.9%, despite the advances made in terms of diagnosis and
treatment. Therefore, we are faced with the problem of finding more effective methods
that allow for an earlier diagnosis and the improved treatment of lung cancer. This study
attempts to address these issues by investigating Tarsh, a novel molecule that is involved in
the regulation of cellular senescence. Previous studies have shown that Tarsh is expressed
in normal lung cells, but is significantly downregulated in lung tumors. These studies also
x

determined that Tarsh is likely dependent upon the expression of p53, a tumor suppressor
gene. The current study investigated these results, in addition to the biological effects of
ectopically increasing Tarsh and/or knocking down p53 expression in two lung cancer cell
lines: A549 and H1299 cell lines. It was determined that increasing the expression of
Tarsh decreased the rate of proliferation in both cell lines. Additionally, it was shown that
the knockdown of p53 increased proliferation in A549 cells. In regards to the migration
rate of these cell lines, the overexpression of Tarsh decreased migration in A549 cells, but
had no effect on H1299 cells. However, the role of p53 in migration is still unclear. The
results of this study suggest that the knockdown of p53 decreases cell migration in A549
cells. This contradicts the fact that H1299 cells do not express p53, yet was found to have
the highest migration rate. It is evident that a further investigation is needed to make more
concrete conclusions. Nevertheless, the suppressive features of Tarsh on cell proliferation,
and possibly migration, make it a promising target of research for lung cancer therapy.

xi

Introduction

1.1: Cancer
Each year, cancer causes about 570,000 deaths, equating to about 25% of the
annual mortalities, in the United States(7). In addition, cancer affects people on a global
scale, claiming numerous lives due to its high adaptability. In essence, it is an ailment
involving the uncontrolled growth of cells in the body. Failure rates with treatment, and
high mortality rates associated with cancer, can be contributed to the ability of these cells
to metastasize. This results in the spreading of the cells to adjacent tissues, and eventually
distant organs(3).
Cancer types may be grouped into five categories, which include carcinomas,
sarcomas, leukemias, lymphomas, and cancers of the central nervous system (CNS).
Carcinomas are cancers that arise from the skin, or in tissues that border internal organs.
Carcinomas can be further divided into subtypes, based on their histology.

These

subdivisions include adenocarcinomas, basal cell carcinomas, squamous cell carcinomas,
and transitional cell carcinomas. Sarcomas are cancers that originate in connective or
supportive tissue, such as cartilage, bone, muscle, fat, and blood vessels. Leukemias
develop from blood-forming tissues, and produce an excess of abnormal white blood cells.
These abnormal cells eventually replace pre-existing, normal white blood cells.
1

Lymphomas are cancers that involve the lymphatic system, a subdivision of the immune
system. These cancers may be categorized as either Hodgkin type lymphomas, which
develop from abnormal B-cells, or non-Hodgkin type lymphomas, which develop from
abnormal B-cells or T-cells. Finally, CNS cancers start in the tissues of the brain and
spinal cord, and arise mainly from astrocytes, the cerebellum, or the spinal cord(18).
Regardless of origin, however, all cancers are believed to be the product of genetic
mutations in normal cells. These newly transformed cells result in a tumor phenotype, and
they often gain the ability to proliferate, survive, and invade surrounding tissues without
limit. Under normal circumstances, these physiological processes are highly regulated.
However, in the case of tumor phenotypes, the deregulation of these processes leads to
cancer metastasis.

The downregulation of these inhibitory effects may be linked to

mutations in tumor-suppressor genes. Normally, these genes function to limit cell growth,
but their inactivation during cancer leads to uncontrolled proliferation. The activation of
another set of genes, known as proto-oncogenes, may also result in a cancer phenotype.
These genes function to enhance cell growth, and in cancer, their levels are overexpressed.
It is likely that mutations in both tumor-suppressor and proto-oncogenes act
synergistically. Therefore, a combination of mutations in both of these genes may cause
abnormal protein expression and characteristics that lead to tumor phenotypes(11).
Environmental factors that contribute to the genetic mutations associated with
cancer include smoking, alcohol, and ultraviolet (UV) radiation exposure.

Routinely

consuming alcohol significantly increases the risk of developing cancer. Previous studies
have shown a positive correlation between alcohol consumption and cancer development,
2

particularly in upper aerodigestive tract carcinomas. Specifically, ethanol has been found
to be the main culprit responsible for cancer formation. Ethanol can aid in the absorption
of other carcinogens by acting as a solvent for entrance into the mucosal tissues. As a
result, using alcohol with other drugs can have synergistic effects.

Previous studies

suggest that the effects of alcohol and smoking are multiplicative.

About 75% of

aerodigestive tract carcinomas can be credited to the simultaneous use of alcohol and
tobacco. In addition, various in vivo and in vitro studies suggest that the metabolic
byproduct of alcohol, acetaldehyde, possesses toxic effects. Acetaldehyde has the ability
to disrupt DNA synthesis, DNA repair sites, and the checkpoints involved in cell
replication.

Therefore, ethanol and acetaldehyde synergistically promote cancer

development(20,29).
The chemicals in tobacco smoke are also associated with cancer, producing
damaging effects on DNA. Benzo(a)pyrene, which binds to cells in the airways and
organs of smokers, has been shown to be the most damaging carcinogen in tobacco smoke.
Consequently, lung cancer is frequently attributed to smoking. The risk of developing lung
cancer is directly associated with the number of cigarettes smoked. Other carcinomas,
such as cancers of the bladder, kidney, cervix, oral cavity, stomach, pancreas and
esophagus, are also linked to tobacco use(19).

3

Figure 1: Cancer Rates Attributable to Smoking. The percentage of various cancers
caused by smoking. The upper aerodigestive tract is most affected(19).

Ultraviolet (UV) radiation from the sun can lead to the development of various skin
cancers, such as cutaneous malignant melanoma, basal cell carcinoma, and squamous cell
carcinoma. UV radiation can be divided into three categories (UV-A, UV-B, and UV-C).
UV-A and UV-B are usually linked with the development of skin carcinomas in humans.
UV-B has the ability to cause direct damage to DNA through the formation of pyrimidine
dimers. Whenever DNA repair mechanisms fail, the resulting mutations can propagate to
future cell generations via cell divisions. UV-B can also form highly reactive oxygen
species (ROS) and damage DNA. Furthermore, UV-A and UV-B radiation can promote
the expression of anti-apoptotic proteins. Although preventable, the frequency of skin
cancer and mortality has been increasing over the last 10 years(3,30).

4

1.2: Lung Cancer Cell Carcinoma
Lung Cancer Cell Carcinoma (LCCC) is the second most common malignancy in
the United States; it is estimated that over 228,000 new cases will arise this year. The
majority of lung cancers originate from epithelial cells that line the air passages in the
lungs.

The two most common types of lung cancer are classified based on their

histological appearance: small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). SCLC accounts for about 12.5% of lung cancer cases. These cells tend to grow
aggressively and metastasize quickly. In contrast, NSCLC is responsible for about 87.5%
of lung cancer cases. Compared to SCLC, these cells are larger in size and develop more
slowly(18). Additionally, studies have shown that the long-term use of tobacco products
accounts for 90% of lung cancers(5). However, it is possible for non-smokers to develop
lung cancer as well. Non-smokers may tumors develop due to genetic factors, secondhand
smoke, air pollution, radon gas, and asbestos(5,24).
LCCC treatments are tailored based on the stage and type of lung cancer. In the
early stages, the cancer is localized to one side of the chest. If the cancer is aggressive or
advanced, it commonly spreads to the lymph nodes and other organs. Lung cancer patients
with an early diagnosis may be eligible for surgical removal of the primary tumor. In
addition, radiotherapy and chemotherapy are other options available at any stage of the
disease(18). Admittedly, lung cancer is difficult to control with current treatments. In
addition, only 15% of patients are diagnosed at an early stage. As a result, the 5-year
prognosis remains poor. Previous research shows that the overall 5-year survival rate for

5

2002-2008 was 15.9%(9). Therefore, it is evident that new, viable treatments are necessary
to improve patient survival.

Table 1: Lung Cancer Stage Distribution and 5-year Survival.

The average 5-year

survival rate of cancer patients is compared to that of the general population. The majority
of patients are diagnosed when the cancer has advanced to later stages(9).
.
1.3: p53 and its Effects on Cancer
Protein 53 (p53) is a well-known tumor suppressor that regulates the cell cycle and
apoptosis in multicellular organisms. In humans, it is encoded by the TP53 gene located
on chromosome 17(16,10). Due to its role in maintaining genomic stability, p53 has been
described as "the guardian of the genome"(21). The p53 protein is made of 393 amino
acids, and has four domains: a domain that activates transcription(26), a core domain that
binds DNA(12), a domain involved in the tetramerization of p53(6), and a domain that
recognizes damaged DNA(4).
In normal cells, the expression p53 protein is low. However, cellular stresses, such
as DNA damage, may increase its production. A rise in p53 expression leads to growth
arrest at the G1/S regulation point in the affected cells, which in turn prevents the
replication of damaged DNA. During cell cycle arrest, p53 also activates genes that
6

produce DNA repair proteins. Once the DNA is repaired, cell cycle inhibition comes to an
end. However, if the DNA is irreparable, p53 can initiate apoptosis in the damaged cells.
In this manner, the proliferation of cells with abnormal DNA is prohibited(2).
Due to the fact that p53 causes potent downstream effects, its expression needs to
be regulated.

Although it can inhibit tumor growth, high levels of p53 may cause

unnecessary apoptosis and result in premature aging. A regulatory gene, Mdm2, functions
to regulate the expression of p53. As p53 becomes activated, the expression of Mdm2 is
also increased.

Mdm2 then downregulates the expression of p53 by labeling it for

degradation with ubiquitin(2).

Figure 2: Simplified Scheme of the p53 Pathway. Cellular stress leads to increased
expression of p53, which in turn activates downstream genes involved in growth arrest,
DNA repair, and apoptosis.

Increased p53 expression leads to increased Mdm2

expression, which in turn negatively regulates p53(14).
7

Defective p53 can result in the reduction of tumor suppression and lead to tumor
formation. In over 50% of all cancers, the p53 gene is either mutated or deleted, resulting
in the expression of a non-functional mutant p53 protein. This loss-of-function mutation
results in the deregulation of the cell cycle and apoptosis, which may lead to the
uncontrolled growth of cells. Previous research also implies that p53 plays a role in cell
migration and invasion. In addition, recent studies suggest that gain-of-function mutations
may occur in p53, which may play a role in promoting cell migration, invasion, and
metastasis(17).
The numerous studies on p53 have led to the increased understanding of processes
involved in tumorigenesis. Although cancer therapies have yet to be derived from these
findings, it is clear that p53 is a powerful mediator of various cell functions, and that the
formation of most tumors is dependent on the inactivation of p53. In effect, this makes
p53 a valuable target for cancer treatment.

1.4: Tarsh and Cellular Senescence in Lung Cancer
Cellular senescence, or aging, is an unavoidable process that all cells in the body
eventually undergo. It was predominantly observed in cultured human fibroblast cells that
entered an irreversible non-dividing state. Recent studies have reported that the shortening
of telomeres may contribute to this process. Furthermore, these studies have also shown
that senescence could be stimulated by extrinsic factors unrelated to telomere length.
These factors included oxidative stress, UV exposure, and oncogenic gene activation. The
role of other senescence-related genes, such as p53, has been investigated, though not
8

much is known about the overall process of senescence at this point. However, these
studies suggest that senescence is likely involved in the elimination of damaged cells,
which in turn suppresses tumor formation(25).
Recent findings suggest that Tarsh, a novel target of NESH-SH3, is a molecule
involved in the regulation of senescence.

Lung carcinomas were specifically chosen

because the presence of Tarsh was detected in mouse lung. It was also determined that
Tarsh expression increased during senescence of mouse embryonic fibroblasts (MEFs)(25).
Other results have indicated that Tarsh is strongly expressed in normal lung cells, and that
Tarsh is significantly downregulated in lung tumors. This downregulation in expression
coincided with a decrease in a tumor’s ability to proliferate and invade surrounding areas.
These results suggest that the loss of Tarsh in lung cancer cells may contribute to
tumoriogenesis(23).

Figure 3: Tarsh Expression in 15 Lung Cancer Strains. The relative mRNA expression of
Tarsh in various lung cancer cell lines, compared to that of normal lung cells.
significant reduction in Tarsh expression was observed in all 15 strains(23).
9

A

1.5: Interactions Between p53 and Tarsh
Another study investigated a possible link between Tarsh and p53 by using a
senescence-associated β-galactosidase (SA-β-gal) activity assay in MEFs. Stained cells
would indicate that the cells were aging. In preparation for this assay, the expression of
Tarsh was knocked down in previously derived wild type (WT) and p53 knockdown (KD)
MEFs. These cells were then compared to WT and p53 KD MEFs with normal Tarsh
expression. The results of this study indicated that TARSH suppression lead to a decrease
in the staining of MEFs, and therefore reduced cellular senescence(28).
The same study also examined the effects of Tarsh suppression on various cancer
related genes. Other than p53, only one other gene was activated in response to the
downregulation of Tarsh. It was determined that p21, a known p53-dependent cyclindependent kinase inhibitor (CKI), was increased in Tarsh-depleted cells(28). Generally, p21
suppresses cell growth via the induction of cell cycle arrest and the inhibition of gene
transcription and apoptosis. These anti-proliferative properties are important in promoting
cellular senescence(1). However, an increase in p21 activity was only observed in WT
MEFs, which expressed p53. No increase in p21 was detected in p53 KD MEFs(28). These
results imply that Tarsh plays a role in p53-dependent cellular senescence in MEFs.

10

Figure 4: Tarsh Expression in p53 KD MEFs. The relative mRNA expression of Tarsh in
p53 KD MEFs, compared to that of WT MEFs.

A significant reduction in Tarsh

expression was observed in p53 KD MEFs(kunihiko).

1.6: Implications of Tarsh in Lung Cancer
As previously discussed, lung cancer is one of the leading causes of mortality in the
United States. The 5-year survival rate for lung cancer patients is very low, which can be
attributed to the fact that its diagnosis usually occurs in later stages. Therefore, there is a
dire need to develop effective methods for the early diagnosis and treatment of lung
cancer. Recent studies have demonstrated a significant reduction in the expression of
Tarsh in lung tumors. This information may prove to be beneficial in clinical applications;
measurements of Tarsh expression in patients could be utilized to determine if cells have
become malignant. In addition, further investigation into the mechanisms of how Tarsh
contributes to cellular senescence could lead to the development of novel therapies.
11

1.7: Hypothesis and Rationalization for the Current Study
The rationalization for this study is to further investigate the biological roles of
Tarsh and p53 in various lung cancer cell lines. These cell lines include A549 Wild-Type
(WT) cells, A549 p53 KD (Knockdown) cells, and H1299 cells. This study will examine
in vitro proliferation and migration rates of these cells, which express varying levels of
p53, depending on the cell line. In turn, the study will verify the effectiveness of Tarsh in
regards to tumor suppression, while determining its dependency on p53. The hypothesis of
this study is that the overexpression of Tarsh will reduce cancer-development related
processes, such as cell proliferation, motility, and survival. In addition, based on previous
findings, it is hypothesized that Tarsh is dependent on the presence of p53, and that the
effects of Tarsh and p53 may be synergistic.

12

Materials and Methods

2.1: Cell Lines and Culture

2.1.1: Cell Line Preparation
A549 adenocarcinomic human alveolar basal epithelial cells were originally
obtained from a 58-year-old Caucasian male patient (explanted tumor), and H1299 human
non-small cell lung carcinoma cells were extracted from a 43-year-old Caucasian male
patient (lymph node). The cells were purchased from commercial vendors, and were
frozen at -80°C. When ready for use, the cells were placed in a 37°C water bath to thaw.
The cells were then suspended in a solution of 10 mL of Dulbecco’s modified Eagle’s
medium (DMEM) (Mediatech, Manassas, VA), 10% Fetal Bovine Serum (FBS), and
specific antibiotics depending on the cell line. The A549 WT and H1299 cell medium was
treated with 100 µg/mL streptomycin, 100 µg/mL neomycin, and 100 µg/mL puromycin.
The A549 p53 KD cell medium was treated with 100 µg/mL streptomycin and 100 µg/mL
puromycin. Afterward, the cells were placed on 10 cm tissue culture plates. Each tissue
culture plate was placed in a humidified incubator at 37°C with a 10% CO2 control and
90% air to allow for growth. The cells were washed with phosphate-buffered saline (PBS),
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and cultured in the same media solution every two to three days for maintenance until
needed.

2.1.2: Transfection of Tarsh and Knockdown of p53
To establish cell lines overexpressing Tarsh, 10 µg of DNA construct was
transfected into 5 × 106 A549 WT, A549 p53 KD, and H1299 cells by electroporation
using a Gene Pulser II (Bio-Rad Laboratories Inc.). To create controls for each cell type, a
pcDNA3.1 vector was transfected into these cells. The resulting clones were isolated after
three weeks of selection in neomycin and puromycin selection media. These cells were
then seeded onto 10 cm plates and incubated to allow for cell expansion. For each cell
line, the expression of Tarsh was determined with quantitative real-time polymerase chain
reaction analysis (qRT-PCR).
p53 knockdown in A549 WT and A549 WT Tarsh transfected cells were generated
by using lentivirus expressing short hairpin RNA (shRNA) against p53.

Lentivirus

systems (Open Biosystems) were utilized, following the manufacturer’s protocol. Clones
were isolated after three weeks of selection in neomycin and puromycin selection medium.
These cells were then seeded onto 10 cm plates and incubated to allow for cell expansion.
For each cell line, the expression of p53 was determined with qRT-PCR.

2.1.3: Cell Maintenance
Once the cells reached 100% confluency, they were split. The each cell plate was
washed twice with 10 mL PBS, and then 1 mL of 0.5% trypsin was added. The cells were
14

then incubated for 5-15 minutes for detachment. To ensure proper detachment from the
plate, the detachment of cells after administration of trypsin were confirmed with the
microscope. Afterward, the cells were incubated to allow for continued healthy expansion.

2.1.4: Cell Stock Preparation
Long-term storage of cell lines was prepared by making cell stock solutions in
cryovials. 5 mL of media was added via jet flow to each 10 cm plate of cells after
detachment with 1 mL of 0.5% trypsin. The cell-media solution was then collected,
pipetted into a 15 mL vial, and centrifuged at 800 rpm for 5 minutes at 4 degrees Celsius.
After centrifugation, the media supernatant was removed by aspiration, leaving a cell pellet
intact. The pellet was lightly tapped and 2 mL of Bambanker serum-free cell freezing
medium (Lymphotec Incorporated, Tokyo, Japan) was added to form a suspension. With
each 2 mL suspension, 4-5 cryovials were produced and placed in an -80°C freezer for
later use.

2.2: Reagents and Antibodies
For use in western blot experiments, the following items were purchased from
commercial vendors: mouse monoclonal p53 primary detection antibodies (Santa Cruz
Biotechnology Incorporated, Catalog Number: sc-126, Lot H1903S), rabbit monoclonal αtubulin primary detection antibodies (Cell Signaling Technology Incorporated, Catalog
Number: 2125S, Lot 11H10), anti-rabbit IgG secondary detection antibodies (Cell
Signaling Technology Incorporated, Catalog Number: 7074), and anti-mouse IgG
15

secondary detection antibodies (Cell Signaling Technology Incorporated, Catalog Number:
7076).

2.3: RNA Extraction
RNA was extracted from 60 mm plates at 80% confluency using an RNeasy Mini
Kit with RNeasy spin columns, QIAGEN® Shredder, and RNase-Free DNase Set
according to protocol provided by the manufacturer (QIAGEN® Incorporated). The RNA
was then stored at -80°C until it was needed. The purity of the RNA was confirmed by
using the NanoDrop ND-1000 spectrophotometer with 1 µL of RNA sample (Thermo
Fisher Scientific).

2.4: Reverse Transcription
Complementary DNA (cDNA) was produced using the High Capacity cDNA
Reverse Transcription achieve kit (Applied Biosystems). To produce cDNA, 1 µg of RNA
was reverse-transcribed with a total volume of 20µL of 2X RT Master Mix (10x reverse
transcriptase buffer, 25x deoxyribonucleotide triphosphate mix, 10x RT random primer,
MultiScribeTM reverse transcriptase, RNase inhibitor, and nuclease-free water). A fourstep reaction was conducted in a thermal cycler: 10 minutes at 25°C, 120 minutes at 37°C,
5 minutes at 85°C, and infinite minutes at 4°C. The generated cDNA was then stored at 20°C for later use.
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2.5: Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR)
qRT-PCR is a method utilized to measure mRNA expression in cells. Previously
generated cDNA is needed for this assay, and is obtained from the Reverse Transcription
assay, as described in chapter 2.4. Taqman® qRT-PCR was performed using primers to
the two genes of interest (Tarsh and p53), and also the housekeeping gene glyceraldehyde3-phosphate-dehydrogenase (GAPDH). GAPDH served as a positive homogenous control.
Taqman® Gene Expression Assay primer Mm00618913_m1 for Tarsh (Applied
Biosystems), primer Hs01034249_m1 for p53 (Applied Biosystems), and Taqman® 20x
GAPDH primer probe dye: FAM-MGB (Applied Biosystems) were utilized.
The qRT-PCR reaction was carried out in triplicate on a 96-well optical reaction
plate. Each well was comprised of 5 µL cDNA, 10 µL Taqman® 2x Universal PCR Master
Mix (Applied Biosystems), 1 µL 20x primer, 4 µL distilled water, for a total volume of 20
µL/well. Afterward, the GAPDH primers were diluted to a 1:10 ratio. The plate was then
sealed with a self-adhesive optical cover, and placed into the qRT-PCR machine.
The cDNA was then amplified using the 7500 HT Fast Real-Time PCR System
(Applied Biosystems).

The process involved the following steps: activation for two

minutes at 50°C, then denaturation for 20 seconds at 95°C, followed by 40 cycles of
melting for three seconds at 95°C, and finally annealing/extending for 30 seconds at 60°C,
respectively. Using SDS 2.2 software, the average ΔΔCT values were calculated and
relative quantification (ΔRQ) was measured.
between the targets and GAPDH was calculated.
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Finally, the difference in ΔRQ values

2.6: Western Blot Assay
Cellular proteins from each cell line were extracted from cultured cells. These
proteins were resolved in 12% denaturing polyacrylamide gels with 0.1% SDS. The
proteins were resolved for 1 hour and 30 minutes at 125 V in 1x SDS-PAGE running
buffer. Next, the proteins were transferred onto a polyvinylidene difluoride membrane
(BioRad Laboratories) after it was briefly soaked 100% methanol. The transfer occurred in
a 1x transfer buffer solution at 8 mA, and was run overnight.
After the transfer was completed, it was necessary to block the membrane. The
membrane was gently rocked in a solution comprised of 2.5 g of dry milk dissolved in 50
mL of 1x Tris-Buffered Saline and Tween-20 (TBST) for 30 minutes. The membrane was
then was washed three times for 5 minute periods. Afterward, the primary antibody was
diluted in a 5% TBST/milk or 1% bovine serum albumin (BSA) solution to generate a
1:1000 concentration. The membrane was gently rocked overnight at 4°Cl. Next, the
membrane was washed three times for 5 minutes each in TTBS. Adding the antibody to a
TBST/milk solution produced a 1:10,000 secondary dilution. The membrane was then
gently rocked in this solution for 1 hour at room temperature. The membrane was washed
for two 10-minute periods and one 30-minute period in TTBS.
Next, the membrane was prepared for film exposure by placing the membrane in a
solution comprised of 500 µL of enhancer solution and 500 µL of peroxide buffer for five
minutes (Western Lightning Chemiluminescence Plus System). The membrane was then
wrapped in saran wrap, placed inside a cassette, and taken to a dark room. Blue Devil
autoradiography film (Genesee Scientific) was placed onto the membrane and the cassette
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was closed for a specific amount of time, depending on the primary antibody used.
Finally, the film was placed into a Kodak photo-processing developer machine for
exposure.

2.7: Cell Proliferation Assay
In preparation for this experiment, cultured cells were allowed to reach between 4060% confluency on 10 cm plates. Cells were then washed twice with 5 mL PBS, and then
detached from their culture plates using 1 mL of trypsin and placing the cells in a 37°C
incubator for 15 minutes. These cells were seeded in triplicate in 24-well cell culture
plates, and diluted to a density of 2 x 103 cells/mL in medium. The cells were then placed
in a 37°C incubator for a 24-hour growth period.
Following the initial growth period, the first triplicate was washed twice with 1 mL
of PBS. After aspiration of the PBS, 200 µL of trypsin was pipetted into each well. The
cells were then placed back into the incubator for 15 minutes to allow for cell detachment.
After detachment, cells from each well were placed into separate eppendorf tubes. A 20
µL volume from each eppendorf tube was then pipetted into a hemocytometer (Improved
Neubauer Haemocytometer) chamber for cell counting.
The hemocytometer was then placed under a light microscope, and cells were
found to reside in a nine-box grid. Counting of the cells was performed in each of the four
corner grids (Figure 10). An average number of cells per well was obtained by dividing
the total number of counted cells by four. This was repeated for all three samples for each
cell derivative. These steps were repeated daily, for a total of six days. After the end of
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the assay, the data was compiled in Excel and a proliferation curve was generated for each
cell line. Tarsh transfected cells were compared to their respective controls to determine
the effects of Tarsh on proliferation. Similarly, A549 p53 KD cells were compared to
A549 WT cells to ascertain the effects of p53 on proliferation.

Figure 5: Hemocytometer Counting. Cell counting was performed in the four
areas indicated by the arrows.

2.8: Cell Migration Assay
In preparation for this experiment, cultured cells were allowed to reach between 4060% confluency on 10 cm plates. Cells were then washed twice with 5 mL PBS, and then
detached from their culture plates using 1 mL of trypsin and placing the cells in a 37°C
incubator for 15 minutes. These cells were seeded in triplicate in 24-well cell culture
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plates, and diluted to a density of 2.5 x 105 cells/mL in medium.

The cells were then

placed in a 37°C incubator for a 24-hour growth period.
After the growth period, a sterile P200 pipette tip was utilized to create a scratch
wound across each well (from top to bottom) in the 24-well plate. The scratch distance
was measured at the time of the scratch (time = 0 hours). A ZEISS® Axiovert 200M
microscope with AxioVision® digital image processing software was utilized to capture
scratch distances in two different areas each scratch. Cells were then incubated for eight
hours, resulting in the migration of cells and a reduction in the size of the scratch.
At the end of the incubation period (time = 8 hours), images were captured at the
same two areas in each well. Each image at time = 8 hours was compared to its respective
image at time = 0 hours. Tarsh transfected cell lines were compared to their respective
controls to determine the effects of Tarsh on migration. Similarly, A549 p53 KD cells
were compared to A549 WT cells to ascertain the effects of p53 on migration.

To

calculate the difference in migration, the following formula was used:

𝑀𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛  𝑅𝑎𝑡𝑒 =

𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  0  ℎ𝑜𝑢𝑟𝑠 − (𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  8  ℎ𝑜𝑢𝑟𝑠)
∗ 100%
𝑆𝑐𝑟𝑎𝑡𝑐ℎ  𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑎𝑡  0  ℎ𝑜𝑢𝑟𝑠

2.9: Statistical Analysis
Comparisons between two groups were analyzed by using an unpaired t-test
analysis with Excel and GraphPad software. A p-value < 0.05 was considered to be
statistically significant.
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Results

3.1: Tarsh Expression Confirmation with qRT-PCR Analysis
To investigate the biological role of Tarsh in A549 WT, A549 p53 KD, and H1299
cell carcinomas, the mRNA expression of Tarsh was examined in Tarsh transfected cell
lines. For all of the cell types, BEAS-2B cells (normal epithelial lung cells) were used as a
baseline for comparison. This information was needed before subsequent experiments
could be performed to determine the effects of Tarsh on survival, proliferation, and
migration.
In all of the lung cancer cell lines, all control cells were found to have a negligible
expression of Tarsh. A549 WT Tarsh transfected cells were found to have 9.2% greater
Tarsh expression, when compared to BEAS-2B cells. A549 p53 KD Tarsh transfected
cells displayed a 66.3% reduction in Tarsh expression, when compared to BEAS-2B cells.
Tarsh expression of H1299 Tarsh transfected cells was reduced by 56.7%, when compared
to BEAS-2B cells. All of these differences were observed to be significant (Figure 6).
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* p < 0.05, **** p < 0.0001

Figure 6: Tarsh Expression. RNA was extracted from near-confluent cultures of BEAS2B, A549, and H1299 cells and reverse transcribed. Afterward, qRT-PCR was performed
as previously described in Materials and Methods. Tarsh expression was standardized to
the GAPDH, the homogenous control. The PCR was performed in triplicate and relative
means ±SEM are shown. A statistically significant decrease in Tarsh expression was
found in A549 WT control cells, A549 p53 KD control cells, and H1299 control cells.
A549 WT Tarsh transfected cells, A549 p53 KD Tarsh transfected cells, and H1299 Tarsh
transfected cells displayed Tarsh expression within physiological ranges, thus confirming
that any future experiments with these cell lines will be physiologically relevant.
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3.2: p53 Downregulation Confirmation with qRT-PCR Analysis
To investigate the biological role of p53 in A549 WT, A549 p53 KD, and H1299
cell carcinomas, the mRNA expression of p53 was examined in these lung cancer cell
lines. For all of the cell types, the A549 WT control cells were used as a baseline for
comparison.

This information was needed before subsequent experiments could be

performed to determine the effects of p53 on survival, proliferation, and migration.
A549 WT Tarsh transfected cells were found to have 38.1% higher levels of p53
expression compared to the A549 WT control cells. However, this was not found to be
statistically significant and was considered to be similar to the baseline. Both A549 p53
KD control cells, and A549 p53 KD Tarsh transfected cells showed a significant decrease
in p53 expression, with an 81.6% reduction (Figure 7).
Similarly, both H1299 control cells and H1299 Tarsh transfected cells displayed a
significant decrease in p53 expression, with a 75% reduction (Figure 7). Although this
PCR experiment suggests that some p53 expression is still present in H1299 cells, this is
not true of H1299 cells. As confirmed by previous findings(15), and by the western blot to
be discussed in the next section, these cells do not produce any functional p53 protein.
This discrepancy can be explained by the fact that the p53 probe used in this experiment is
detecting the partially deleted p53 gene in these cells.
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** p < 0.01

Figure 7: p53 Gene Expression. RNA was extracted from near-confluent cultures of A549
and H1299 cells and reverse transcribed.

Afterward, qRT-PCR was performed as

previously described in Materials and Methods. The p53 expression was standardized to
the GAPDH, the homogenous control. The PCR was performed in triplicate and relative
means ±SEM are shown. A statistically significant decrease in p53 expression was found
in A549 p53 KD cell lines and H1299 cell lines, when compared to A549 WT control
cells.
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3.3: p53 Protein Expression Confirmation with Western Blot
To validate the previous results of the qRT-PCR in regards to p53 (Figure 2), it was
necessary to perform a western blot analysis. A549 WT, A549 p53 KD, and H1299 cells
were lysed, and gel electrophoresis was performed. The proteins were then transferred
onto a membrane, which were detected with specific antibodies.

This protocol was

previously described in Materials and Methods. In this experiment, α-tubulin was used as
the control.
The results of this experiment confirm the previous results of the qRT-PCR in
regards to p53. It is clear that p53 protein expression levels in A549 WT cells are similar
to that of tubulin. In addition, p53 protein expression is significantly downregulated in
A549 p53 KD cell lines. In regards to H1299 cell lines, the western blot shows that these
cells are not producing p53 protein (Figure 8).

26

Figure 8: Western Blot Analyzing p53 Protein Expression. A549 WT, A549 p53 KD, and
H1299 cells were lysed and gel electrophoresis was performed.

The proteins were

subsequently transferred to a membrane, and specific antibodies were utilized to determine
the total molecule content of tubulin and p53. Tubulin was the control in this experiment.
A549 WT cell lines had a comparable amount of p53 protein to tubulin. A549 p53 KD cell
lines displayed a significant reduction in p53 protein production. H1299 cell lines did not
produce p53 protein. Three trials were performed for this experiment.
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3.4: Tarsh Overexpression Suppresses Proliferation in All Cell Lines
The proliferation and growth of cells in lung cancer contribute to the progression
and metastasis of the disease. Therefore, it was important to observe the proliferation rates
of all the cell lines involved in the study. Once the stability of the Tarsh transfected cell
lines was confirmed by qRT-PCR (Figure 6), the cells were prepared for cell proliferation
assays to measure their growth rates. In these assays, each cell line’s respective control
vector served as a basis for comparison. Each cell line was diluted to a density of 5 x 103
cells/mL in its respective selection medium conditions. The cells were then plated, in
triplicate, onto 24-well plates (though only 18 wells were needed). A 24-hour latency
period was allowed for initial growth to occur. For the following six days, cells in three
out of the 18 wells were trypsinized and counted.

The triplicated results were then

averaged.
As shown in Figure 9, A549 WT Tarsh transfected cells exhibited an average
reduction of 38% in growth when compared to A549 WT control cells. Starting from day
3, a statistically significant difference was observed with a p-value < 0.05. From days 4-6,
the difference was extremely significant, with a p-value < 0.0001. Similarly, the average
proliferation of A549 p53 KD Tarsh transfected cells was reduced by about 40% when
compared to A549 p53 KD control cells (Figure 10). This decrease was also found to be
statistically significant starting from day 2. Finally, Figure 11 shows that Tarsh also
suppresses proliferation rates in H1299 cell lines. H1299 Tarsh transfected cells exhibited
an average reduction of about 33% in growth when compared to H1299 control cells. The
difference in growth was considered to be statistically significant.
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* p < 0.05, **** p < 0.0001

Figure 9: A549 WT Proliferation. A549 WT cells were diluted to a density of 2 x 103
cells/mL and were allowed a 24-hour growth period before counting began. In each trial,
the cells were seeded in triplicate. An average number of cells were calculated each day
for a total of six days. The mean cell counts and the ±SEM are shown. Starting from day
3, a significant reduction in proliferation was observed in A549 WT Tarsh transfected cells
when compared to A549 WT control cells. The number of trials ranged from six to seven
for each cell line.
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* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

Figure 10: A549 p53 KD Proliferation. A549 p53 KD cells were diluted to a density of 2
x 103 cells/mL and were allowed a 24-hour growth period before counting began. In each
trial, the cells were seeded in triplicate. An average number of cells were calculated each
day for a total of six days. The mean cell counts and the ±SEM are shown. Starting from
day 2, a significant reduction in proliferation was observed in A549 p53 KD Tarsh
transfected cells when compared to A549 p53 KD control cells. The number of trials
ranged from three to five for each cell line.
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* p < 0.05, ** p < 0.01, **** p < 0.0001

Figure 11: H1299 Proliferation. H1299 cells were diluted to a density of 2 x 103 cells/mL
and were allowed a 24-hour growth period before counting began. In each trial, the cells
were seeded in triplicate. An average number of cells were calculated each day for a total
of six days. The mean cell counts and the ±SEM are shown. A significant reduction in
proliferation was observed in H1299 Tarsh transfected cells when compared to H1299
control cells. Six trials were performed for each cell line.
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3.5: p53 Downregulation Increases Proliferation in All Cell Lines
In addition to observing the effects of Tarsh on cell growth, it was also important to
determine the effects of downregulating p53 on the proliferation rates of all the cell lines
involved in the study. A direct comparison between A549 WT and A549 p53 KD cells
cannot be made due to differing selection medium conditions between the two. However,
it can be inferred from the results that reducing p53 expression via knockdown in A549
cells increases proliferation, as A549 WT cells (Figure 9) generally had a higher cell count
than A549 p53 KD cells (Figure 10). Similarly, although a direct comparison between
A549 WT cells and H1299 cells cannot be made due to the fact that they are different cell
lines, A549 WT cells (Figure 9) generally had a higher cell count than H1299 cells (Figure
11). This implies that the lack of p53 in H1299 cells caused an increase in the number of
cells.
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3.6: Tarsh Suppresses A549 Migration, H1299 Migration Unaffected
In vitro motility studies can give an indication of how readily a cancer metastasizes
and spreads to distant areas of the body. Therefore, it was also important to observe the
effects of Tarsh overexpression on cellular migration, in addition to proliferation. To
observe the motility of A549 WT and A549 p53 KD cell lines, migration assay were
performed.

Each cell line was seeded across six wells, with each well yielding

quadruplicate measurements. Each cell line was diluted to a density of 2.5 x 105 cells/mL,
and the cells were allowed to grow to 100% confluency. A scratch was made on each well,
and the cells were then incubated for eight hours. At the end of the incubation period, the
cellular migration was calculated using AxioVision® software (Figure 12).
A549 WT Tarsh transfected cells displayed a statistically significant reduction in
migration compared to A549 WT control cells. The difference in migration was 18.5%,
with a p-value < 0.01. Similarly, A549 p53 KD Tarsh transfected cells displayed a
statistically significant reduction in migration compared to A549 p53 KD control cells.
The migration was reduced by 18.2%, and the p-value was less than 0.05 (Figure 13).
However, Tarsh overexpression did not have any effect on H1299 cell migration.
With a difference of only 1.4%, there was no statistically significant reduction when
comparing H1299 Tarsh transfected cells to H1299 control cells (Figure 14).
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A549 WT Control,
time = 0 hours

A549 WT Control,
time = 8 hours

A549 WT Tarsh,
time = 0 hours

A549 WT Tarsh,
time = 8 hours

Figure 12: Cell Migration Assay. A549 WT and A549 p53 KD cells were plated at a
density of 2.5 x 105 cells/mL, and were allowed to reach 100% confluency in their
respective selection medium conditions. The migration assay was performed at time = 0
hours. After an 8-hour incubation period, the migration distances were measured with a
ZEISS® Axiovert 200M microscope and AxioVision® digital imaging software.
Representative images of A549 WT cells are shown at 0 and 8 hours.
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* p < 0.05, ** p < 0.01

Figure 13: Role of Tarsh in A549 Migration. A549 cells were diluted to a density of 2.5 x
105 cells/mL and cultured to confluency.
quadruplicate.

In each trial, the cells were seeded in

After reaching confluency, a migration assay was performed.

A cell

retardation ratio was then calculated based on the migration distance after 8 hours. The
ratios were then averaged and the ±SEM for each cell line was calculated. A549 WT
Tarsh transfected cells displayed a significant reduction in migration compared to A549
WT control cells. Similarly, A549 p53 KD Tarsh transfected cells displayed a significant
reduction in migration compared to A549 p53 KD control cells. The number of trials
ranged from five to six for each cell line.
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Figure 14: H1299 Migration. H1299 cells were diluted to a density of 2.5 x 105 cells/mL
and cultured to confluency. In each trial, the cells were seeded in quadruplicate. After
reaching confluency, a migration assay was performed. A cell retardation ratio was then
calculated based on the migration distance after 8 hours. The ratios were then averaged
and the ±SEM for each cell line was calculated. No significant difference in migration was
observed between the two cell lines. The number of trials ranged from four to five for
each cell line.
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3.7: Role of p53 in Migration is Unclear
In addition to Tarsh, it was also necessary to observe the effects of p53
downregulation on cellular motility. A direct comparison between A549 WT and A549
p53 KD cells cannot be made due to differing selection medium conditions between the
two.

However, it can be inferred from the results that reducing p53 expression via

knockdown in A549 cells decreases the migration rate, as A549 p53 KD cells generally
had a reduced migration distance when compared to A549 WT cells (Figure 13).
However, the opposite was observed when comparing A549 WT cells to H1299
cells. Although a direct comparison between A549 WT cells and H1299 cells cannot be
made due to the fact that they are different cell lines, H1299 cells (Figure 14) generally had
a higher migration distance when compared to A549 WT cells (Figure 13). In this case,
the results imply that reducing p53 expression in cells increases the migration rate.
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Discussion

4.1: Aims of the Current Study
The conclusions made by previous studies have shown that Tarsh expression is
often downregulated in various cancer cell lines, and that re-expression of Tarsh
significantly reduces cell proliferation, migration, and survival(13,24,28).

These results

suggest that the loss of Tarsh expression may play a vital role in the pathogenesis and
progression of various types of cancers. In addition, a previous paper concluded that Tarsh
is dependent upon p53, suggesting that without it, Tarsh may lose its effectiveness(12).
However, only a very limited number of studies have been published, and further
investigation is needed. As a result, the combined effects of Tarsh and p53 on tumor
development are yet to be fully determined.

4.2 The Lung Cancer Cell Carcinoma (LCCC) Model System
In order to effectively study the effects of Tarsh and p53 in LCCC, an in vitro
approach was utilized. Before any experiments were performed, lung cancer cell lines
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were prepared and maintained in culture. The first cell line was the A549 cell line. These
cells were obtained from an explanted tumor of a 58-year-old Caucasian male. For this
study, the A549 cell line was split, and one group was transfected with Tarsh. Each
resulting group was then split again, and p53 expression was knocked down in each group.
This procedure resulted in four cell derivatives: A549 WT control, A549 WT Tarsh
transfected, A549 p53 KD control, and A549 p53 KD Tarsh transfected cells. The H1299
cell line was the second cell line, which was isolated from a lymph node metastasis in a
43-year-old Caucasian male. These cells were split, and one group was transfected with
Tarsh, resulting in two derivatives: H1299 Control and H1299 Tarsh transfected cells.
First, it was necessary to determine the mRNA expression levels of Tarsh in these
cells, due to the fact that half of the cell derivatives were previously transfected with Tarsh.
Therefore, qRT-PCR analysis was performed in the aforementioned cell lines. The results
of the analysis showed that each Tarsh transfected cell line had significantly higher Tarsh
mRNA expression when compared to its respective control (Figure 6). This data provided
some of the foundation of the current study that was needed before any biological assays
could be performed.
It was also essential to determine the expression levels of p53, as its expression was
knocked down in half of the A549 cell derivatives, and is non-existent in H1299 cells. For
this signaling molecule, qRT-PCR and western blot analyses were performed. In these
assays, the p53 expression in A549 WT control cells served as the baseline measurement.
The results of both assays led to the conclusion that p53 expression was highly
downregulated in both A549 p53 KD control and A549 p53 KD Tarsh transfected cells
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(Figures 7 and 8). Similarly, it was shown that both H1299 control and H1299 Tarsh
transfected cells also had significantly decreased p53 expression (Figures 7 and 8).
However, in regards to H1299 cells, it must be stated that a discrepancy was observed
between the two assays. The qRT-PCR assay suggests that some p53 is present in H1299
cells, while the western blot analysis suggests that the cells are not generating any p53
protein. This can be explained by the fact that the p53 probe used in this experiment is
detecting the partially deleted p53 gene in these cells.

4.3: Role of p53 and Tarsh in Cell Proliferation
Previous research has indicated that the expression of Tarsh is downregulated in
various cancer cells(13,24,28). In addition, it is common for p53 functionality to be lost in
cancer, resulting in severely reduced tumor suppression(8). In turn, cells that express p53
and Tarsh inhibited cell proliferation(13,27). Results from the current study indicate that a
decrease in proliferation was observed due to increased Tarsh and increased p53
expression. However, these two genes seem to work independently.
Ectopic overexpression of Tarsh in A549 cell lines caused a significant reduction in
proliferation, when compared to their respective controls (Figures 9 and 10). In A549 WT
cells, an average reduction of 38.0% was observed. Similarly, in A549 p53 KD cells,
proliferation was reduced by an average of 39.7%. H1299 cells behaved similarly to A549
cells; proliferation was reduced by an average of 33.4% in H1299 Tarsh transfected cells
(Figure 11). These findings suggest that Tarsh has an inhibitory effect on proliferation,
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independent of p53. This is due to the fact that regardless of the level of p53 expression,
Tarsh was able to downregulate proliferation in all of the examined lung cancer cell lines.
Although the effects of p53 on cell proliferation could not be directly compared
between the cell lines, either due to differing selection medium conditions or the fact that
the compared groups contained different cell lines, it could be inferred from the data that
p53 has an inhibitory effect on proliferation. It can be generalized that A549 p53 KD cells
had a higher cell count than A549 WT cells due to the fact that its p53 expression was
knocked down in A549 p53 KD cells. Similarly, it can also be generalized that H1299
cells also have a higher cell count because they do not express p53.

4.4: Role of p53 and Tarsh in Cell Migration
Previous findings suggest that Tarsh and p53 expression suppresses cell motility in
cancer cells(13,17).

The results of the current study support the notion that Tarsh

overexpression reduces motility, but only in A549 cells. However, Tarsh overexpression
in H1299 cells did not affect migration. Additionally, a concrete conclusion cannot be
made in terms of the effects of p53 on migration, due to varying results.
The overexpression of Tarsh in A549 cell lines caused a significant reduction in
migration, when compared to their respective controls (Figure 13). In A549 WT cells, an
average reduction of 18.5% was observed. Likewise, in A549 p53 KD cells, proliferation
was reduced by an average of 18.2%. These findings suggest that Tarsh has an inhibitory
effect on migration, independent of p53. This is due to the fact that regardless of the level
of p53 expression, Tarsh was able to downregulate migration in A549 cells.
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However, H1299 cell migration was not affected by ectopic Tarsh overexpression;
only a 1.4% difference in migration was observed (Figure 14). These results could be
explained by the fact that H1299 cells do not have functional p53(15), and are therefore
different from A549 cells. Due to the complete lack of p53 in H1299 cells, they may lack
a p53-dependent pathway in which migration is dependent on in A549 cells. It could be
possible that H1299 cells have circumvented this pathway, or may have even developed a
novel pathway that affects migration. Although p53 expression was highly downregulated
in A549 p53 KD cells, this was artificially created. In reality, A549 cells do express
endogenous p53. Therefore, it is likely that a p53-dependent pathway still exists in A549
p53 KD cells.
Although the effects of p53 on cell migration could not be directly compared
between the cell lines, either due to differing selection medium conditions or the fact that
the compared groups contained different cell lines, it could be inferred from the data that
p53 has opposing effects in A549 cells and H1299 cells. It can be generalized that A549
p53 KD cells had a reduced migration rate, when compared to A549 WT cells, due to the
fact that its p53 expression was knocked down in A549 p53 KD cells. These observations
do not support previous findings. However, it can also be generalized that H1299 cells,
which lack p53, was observed to have the highest migration rate. These results do support
previous findings. The unexpected results of the A549 p53 KD migration assays could
possibly be explained by the use of a differing selection medium. These cells were grown
in a puromycin selection medium, whereas A549 WT and H1299 cells were grown in a
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neomycin and puromycin selection medium. It is possible that the differing conditions
could have impacted the results.

4.5: Conclusions
In this study, it was shown that ectopic overexpression of Tarsh in lung cancer cell
lines decreased cell proliferation and migration, independent of p53.

Additionally,

decreased p53 expression levels coincided with an increase in cell proliferation. However,
the role of p53 in LCCC migration remains unclear. At this point, a more detailed
understanding of the pathway by which Tarsh and p53 interact is required to make more
concrete conclusions. Regardless of this fact, this field of research seems promising in that
it may lead to the development of novel treatments that can suppress tumor malignancy.

4.6: Future Studies
Given that p53 is mutated in many types of cancer(8), supplemental experiments
focusing on cell lines with mutated p53 could be utilized. KNS-62, an epithelial cell line
derived from a brain metastasis of a primary lung tumor(22), has been prepared for future
experiments. Stable Tarsh transfects were produced using the GeneCopoeia® HIV-based
lentiviral expression vector system. Tarsh expression was confirmed via qRT-PCR. The
resulting cell derivatives, KNS-62 control cells and KNS-62 Tarsh transfected cells, were
frozen, made into stock, and stored at -80°C. These cells are ready to be utilized in
proliferation and migration assays.
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In addition, it is necessary to reexamine cell migration in A549 p53 KD cell lines.
The results obtained from this study do not follow the trend that was observed in previous
studies, as well as H1299 cells. As explained in the discussion section, a possible reason
for this outcome could be due to the selection medium used for A549 p53 KD cells.
Repeating the migration experiments with the same selection medium conditions as A549
WT and H1299 cell lines may lead to a more reliable conclusion.
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